Every Form 4 that Klotho Neurosciences, Inc. (KLTO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLTO filings page.
Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.
Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.
Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.
ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.
Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.
Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.
Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.
McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.
Klotho Neurosciences, Inc. reported that Chief Executive Officer Joseph Sinkule acquired 2,500,000 shares of common stock on March 4, 2026 through a grant under the company’s Equity Incentive Plan. The shares were reported at a price of $0.00 per share.
Following this grant, Sinkule’s directly held common stock increased to 6,346,700 shares. This transaction reflects an equity award rather than an open-market purchase or sale.
Joseph Sinkule, who serves as Chief Executive Officer and a Director of Klotho Neurosciences, acquired 400,000 shares of the company's common stock on 09/25/2025. The filing states these shares were returned to him after he canceled a portion of a previously-reported non-recourse loan that had used the shares as collateral. After this transaction, Sinkule beneficially owns 4,846,700 shares, which the filing clarifies includes 1,000,000 shares issuable upon exercise of incentive options. The Form 4 is signed and dated 09/29/2025 and reports the change as a non-derivative acquisition by an executive who is also a director.